Zhejiang Tianyu Pharmaceutical Co.,Ltd.(300702),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

300702 Zhejiang Tianyu Pharmaceutical Co.,Ltd.

Closed 12-23 15:00:00

23.91

+0.18

+0.76%

High23.99	Low23.61	Vol1.66M
Open23.83	D1 Closing23.73	Amplitude1.60%
Mkt Cap8.32B	Tradable Cap5.05B	Total Shares348.00M
T/O39.43M	T/O Rate0.79%	Tradable Shares211.00M
P/B2.22	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"300702","market":"SZ","secType":"STK","nameCN":"Zhejiang Tianyu Pharmaceutical Co.,Ltd.","latestPrice":23.91,"timestamp":1766473398000,"preClose":23.73,"halted":0,"volume":1657841,"delay":0,"changeRate":0.0076,"floatShares":211000000,"shares":348000000,"eps":0.5511,"marketStatus":"Closed","change":0.18,"latestTime":"12-23 15:00:00","open":23.83,"high":23.99,"low":23.61,"amount":39429500,"amplitude":0.016,"askPrice":23.91,"askSize":9,"bidPrice":23.89,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.5511,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766539800000},"marketStatusCode":5,"adr":0,"adjPreClose":23.73,"symbolType":"stock","openAndCloseTimeList":[[1766453400000,1766460600000],[1766466000000,1766473200000]],"highLimit":26.1,"lowLimit":21.36,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":347977159,"isCdr":false,"pbRate":2.22,"roa":"--","peRate":43.385955,"roe":"6.12%","epsLYR":0.16,"committee":0.280607,"marketValue":8320000000,"turnoverRate":0.0079,"status":0,"floatMarketCap":5049000000},"requestUrl":"/m/hq/s/300702","defaultTab":"news","newsList":[{"id":"1100485688","title":"Zhejiang Tianyu Pharmaceutical (300702.SZ) Completes Drug Registration for Candesartan Cilexetil Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1100485688","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100485688?lang=en_us&edition=fundamental","pubTime":"2025-09-04 16:14","pubTimestamp":1756973659,"startTime":"0","endTime":"0","summary":"Zhejiang Tianyu Pharmaceutical Co.,Ltd. (300702.SZ) announced that its wholly-owned subsidiary Zhejiang Nuode Pharmaceutical Co., Ltd. recently received the Drug Registration Certificate for...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300702"],"gpt_icon":0},{"id":"1156100308","title":"Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) Reports First Half Results with Net Profit of 150 Million Yuan, Up 180.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156100308","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156100308?lang=en_us&edition=fundamental","pubTime":"2025-08-22 20:14","pubTimestamp":1755864866,"startTime":"0","endTime":"0","summary":"Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) released its 2025 interim report, showing operating revenue of 15.67 billion yuan, representing a year-over-year increase of 23.87%. Net profit...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2559046746","title":"Zhejiang Tianyu Pharmaceutical Gets EU Certificate for Anti-Hypertensive Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2559046746","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559046746?lang=en_us&edition=fundamental","pubTime":"2025-08-13 20:06","pubTimestamp":1755086782,"startTime":"0","endTime":"0","summary":"The European Union granted Zhejiang Tianyu Pharmaceutical  the European Pharmacopoeia Certificate of Suitability for its formulation of telmisartan, according to a Wednesday filing with the Shenzhen bourse.Telmisartan is indicated for hypertension and the reduction of cardiovascular risk, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","300702","BK4156"],"gpt_icon":0},{"id":"2556807069","title":"Zhejiang Tianyu Pharmaceutical Gets EU Certificate for Epileptic Seizure Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2556807069","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556807069?lang=en_us&edition=fundamental","pubTime":"2025-08-04 17:59","pubTimestamp":1754301558,"startTime":"0","endTime":"0","summary":"The European Union granted Zhejiang Tianyu Pharmaceutical (SHE:300702) the pharmacopoeia certificate of suitability for its brivaracetam active pharmaceutical ingredient.Brivaracetam is indicated as a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4156","300702","BK0239"],"gpt_icon":0},{"id":"2555033312","title":"Tianyu Pharmaceutical's Subsidiary Gets European Certificate for Pharmaceutical Ingredient for Type 2 Diabetes Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2555033312","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555033312?lang=en_us&edition=fundamental","pubTime":"2025-07-29 15:49","pubTimestamp":1753775390,"startTime":"0","endTime":"0","summary":"Zhejiang Tianyu Pharmaceutical's  subsidiary, Zhejiang Jingsheng Pharmaceutical, received a certificate of suitability from Europe for the sitagliptin phosphate active pharmaceutical ingredient.The certificate shows that the product met the region's quality standards and is a step toward the product being approved to be sold within Europe.Sitagliptin phosphate was developed to treat patients with Type 2 diabetes mellitus.The company's shares closed 3% higher.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2555038433","title":"Chinese Stocks Finish With Gains As Trade Talks With US Continue","url":"https://stock-news.laohu8.com/highlight/detail?id=2555038433","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555038433?lang=en_us&edition=fundamental","pubTime":"2025-07-29 15:40","pubTimestamp":1753774809,"startTime":"0","endTime":"0","summary":"Chinese shares closed with gains as trade talks with the US was expected to continue on Tuesday, with hopes that the tariff reprieve will be extended.The Shanghai Composite Index, the main gauge of Chinese stocks, added 0.3%, or 11.77 points, to finish Tuesday's trade at 3,609.71. The Shenzhen Component Index edged up 0.6%, or 71.83 points, to 11,289.41.Chinese economic officials met with their American counterparts in Sweden on Monday to discuss ways to alleviate trade tensions between them as China faces an Aug. 12 deadline to strike a tariff deal with the White House.Neither side discussed the details of the negotiations, which are expected to resume on the following day.In corporate news, Chengdu Easton Biopharmaceuticals  surged 15.5% after its unit, Chengdu Shuode Pharmaceutical, received a drug registration certificate from the Chinese drug administration for perindopril and amlodipine tablets .Zhejiang Tianyu Pharmaceutical  jumped 3.1% after getting a European certificate for ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688513","BK4134","300702","BK0239","III"],"gpt_icon":0},{"id":"2551169134","title":"Zhejiang Tianyu Pharmaceutical Forecasts Up to 238% Rise in H1 Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2551169134","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551169134?lang=en_us&edition=fundamental","pubTime":"2025-07-15 18:55","pubTimestamp":1752576936,"startTime":"0","endTime":"0","summary":"Zhejiang Tianyu Pharmaceutical  expects attributable profit to surge 144% to 238% to between 130 million yuan and 150 million yuan in the first half from 53.2 million yuan in the year-ago period, according to a Monday filing with the Hong Kong bourse.The drug company's upbeat forecast is attributable to improvements in its gross profit and lower foreign exchange derivative transactions, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"1136967639","title":"TianYu Pharma (300702.SZ) Forecasts H1 Profit Surge: Net Profit Expected at 1.3B-1.8B Yuan, Up 144.29%-238.25% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=1136967639","media":"Stock Track","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136967639?lang=en_us&edition=fundamental","pubTime":"2025-07-15 17:18","pubTimestamp":1752571100,"startTime":"0","endTime":"0","summary":"TianYu Stock (300702.SZ) has released an upbeat preliminary earnings forecast for the first half of 2025. The pharmaceutical company anticipates net profit attributable to shareholders will reach 1.3...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2550600446","title":"Zhejiang Tianyu Pharmaceutical Obtains Drug Registration for High Cholesterol Tablets; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550600446","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550600446?lang=en_us&edition=fundamental","pubTime":"2025-07-11 13:27","pubTimestamp":1752211651,"startTime":"0","endTime":"0","summary":"Zhejiang Tianyu Pharmaceutical (SHE:300702) subsidiary Nuode Pharma obtained drug registration from China's medical products administrator for its rosuvastatin calcium and ezetimibe tablets.The drug i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","300702"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-09-19","address":"浙江省台州市黄岩区黄岩江口化工开发区","stockEarnings":[{"period":"1week","weight":0.0284},{"period":"1month","weight":0.0093},{"period":"3month","weight":-0.0829},{"period":"6month","weight":0.0736},{"period":"1year","weight":0.4176},{"period":"ytd","weight":0.438}],"companyName":"浙江天宇药业股份有限公司","boardCode":"AI0027","perCapita":"13857股","boardName":"医药制造业","registeredCapital":"34797万元","compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0222},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1367},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.1695}],"survey":"　　浙江天宇药业股份有限公司的主营业务是中间体、原料药以及制剂业务的研发、生产与销售。公司的主要产品是降血压类原料药及中间体、降血糖类原料药及中间体、抗凝血类原料药及中间体、制剂类、抗哮喘类原料药及中间体、降血脂类原料药及中间体。","serverTime":1766531197256,"listedPrice":22.41,"stockholders":"15238人(较上一季度减少8.06%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zhejiang Tianyu Pharmaceutical Co.,Ltd.(300702),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zhejiang Tianyu Pharmaceutical Co.,Ltd.(300702) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zhejiang Tianyu Pharmaceutical Co.,Ltd.,300702,Zhejiang Tianyu Pharmaceutical Co.,Ltd.股票,Zhejiang Tianyu Pharmaceutical Co.,Ltd.股票老虎,Zhejiang Tianyu Pharmaceutical Co.,Ltd.股票老虎国际,Zhejiang Tianyu Pharmaceutical Co.,Ltd.行情,Zhejiang Tianyu Pharmaceutical Co.,Ltd.股票行情,Zhejiang Tianyu Pharmaceutical Co.,Ltd.股价,Zhejiang Tianyu Pharmaceutical Co.,Ltd.股市,Zhejiang Tianyu Pharmaceutical Co.,Ltd.股票价格,Zhejiang Tianyu Pharmaceutical Co.,Ltd.股票交易,Zhejiang Tianyu Pharmaceutical Co.,Ltd.股票购买,Zhejiang Tianyu Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zhejiang Tianyu Pharmaceutical Co.,Ltd.(300702),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zhejiang Tianyu Pharmaceutical Co.,Ltd.(300702) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}